NASDAQ:ABVX Abivax (ABVX) Stock Price, News & Analysis $96.55 -4.32 (-4.28%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$98.22 +1.67 (+1.73%) As of 06/12/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Abivax Stock (NASDAQ:ABVX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Abivax alerts:Sign Up Key Stats Today's Range$96.21▼$100.9050-Day Range$72.50▼$132.6352-Week Range$5.69▼$148.83Volume1.16 million shsAverage Volume2.86 million shsMarket Capitalization$7.69 billionP/E RatioN/ADividend YieldN/APrice Target$130.08Consensus RatingModerate Buy Company Overview Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles. Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders. This small molecule has completed Phase 2 studies in rheumatoid arthritis and ulcerative colitis, demonstrating promising efficacy signals and a favorable tolerability profile. In addition, Abivax is exploring obefazimod’s antiviral potential in early-stage programs targeting chronic viral infections, including HIV and hepatitis B. With operations in Europe and strategic development activities in the United States, Abivax collaborates with academic institutions and research centers to advance its pipeline. The company is led by a management team with deep expertise in biotechnology development and regulatory affairs. Under the leadership of CEO Pascal Mélin, Abivax pursues its mission to bring innovative, host-targeted therapies to patients worldwide. AI Generated. May Contain Errors. Read More Abivax Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreABVX MarketRank™: Abivax scored higher than 66% of companies evaluated by MarketBeat, and ranked 309th out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAbivax has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 12 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAbivax has a consensus price target of $130.08, representing about 34.7% upside from its current price of $96.55.Amount of Analyst CoverageAbivax has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Abivax's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Abivax are expected to decrease in the coming year, from ($3.40) to ($3.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abivax is -18.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Abivax is -18.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbivax has a P/B Ratio of 14.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.83% of the float of Abivax has been sold short.Short Interest Ratio / Days to CoverAbivax has a short interest ratio ("days to cover") of 2.52, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Abivax has recently increased by 23.12%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbivax does not currently pay a dividend.Dividend GrowthAbivax does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.35 News SentimentAbivax has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Abivax this week, compared to 5 articles on an average week.Search Interest24 people have searched for ABVX on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows2 people have added Abivax to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Abivax insiders have not sold or bought any company stock.Percentage Held by Institutions47.91% of the stock of Abivax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abivax's insider trading history. Receive ABVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abivax and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABVX Stock News HeadlinesAbivax SA Sponsored ADR (NASDAQ:ABVX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 13 at 2:11 AM | americanbankingnews.comABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law FirmJune 11 at 12:00 PM | prnewswire.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.June 13 at 1:00 AM | Altimetry (Ad)Analysts Offer Insights on Healthcare Companies: Phibro Animal Health (PAHC) and Abivax SA Sponsored ADR (ABVX)June 10 at 12:51 AM | theglobeandmail.comLeerink Partners Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX)June 10 at 12:51 AM | theglobeandmail.comABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law FirmJune 10 at 10:15 AM | globenewswire.comEuropean Value Stocks Trading Below Estimated Intrinsic Values June 2026June 10 at 4:37 AM | finance.yahoo.comABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law FirmJune 8, 2026 | prnewswire.comSee More Headlines ABVX Stock Analysis - Frequently Asked Questions How have ABVX shares performed this year? Abivax's stock was trading at $134.85 at the beginning of 2026. Since then, ABVX stock has decreased by 28.4% and is now trading at $96.55. How were Abivax's earnings last quarter? Abivax SA Sponsored ADR (NASDAQ:ABVX) announced its quarterly earnings data on Friday, May, 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.23. The business earned $1.56 million during the quarter, compared to analysts' expectations of $0.40 million. When did Abivax IPO? Abivax (ABVX) raised $230 million in an initial public offering (IPO) on Friday, October 20th 2023. The company issued 18,699,460 shares at a price of $11.60-$13.00 per share. Who are Abivax's major shareholders? Top institutional investors of Abivax include Eversept Partners LP (1.18%), Janus Henderson Group PLC (1.10%), Bank of America Corp DE (0.92%) and Octagon Capital Advisors LP (0.85%). How do I buy shares of Abivax? Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abivax own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abivax investors own include Adverum Biotechnologies (ADVM), APi Group (APG), Avino Silver & Gold Mines (ASM), Boot Barn (BOOT), Howard Hughes (HHH) and KT (KT). Company Calendar Last Earnings5/22/2026Today6/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 11 days, ABVX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABVX Previous SymbolNASDAQ:ABVX CIK1956827 Webwww.abivax.com Phone33-1-53-83-09-63FaxN/AEmployees61Year Founded2013Price Target and Rating Average Price Target for Abivax$130.08 High Price Target$187.00 Low Price Target$74.00 Potential Upside/Downside+34.7%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($5.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$380.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-99.02% Return on Assets-70.26% Debt Debt-to-Equity RatioN/A Current Ratio8.25 Quick Ratio8.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.57 per share Price / Book14.70Miscellaneous Outstanding Shares79,690,000Free FloatN/AMarket Cap$7.69 billion OptionableNot Optionable Beta0.69 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ABVX) was last updated on 6/13/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abivax SA Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Abivax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
